Hydroxychloroquine for COVID-19: Balancing contrasting claims
- PMID: 33243609
- PMCID: PMC7682326
- DOI: 10.1016/j.ejim.2020.11.018
Hydroxychloroquine for COVID-19: Balancing contrasting claims
Comment on
-
Use of hydroxychloroquine in hospitalised COVID-19 patients is associated with reduced mortality: Findings from the observational multicentre Italian CORIST study.Eur J Intern Med. 2020 Dec;82:38-47. doi: 10.1016/j.ejim.2020.08.019. Epub 2020 Aug 25. Eur J Intern Med. 2020. PMID: 32859477 Free PMC article.
References
-
- Collins R, MacMahon S. Reliable assessment of the effects of treatment on mortality and major morbidity, I: clinical trials. Lancet. 2001;357:373–380. - PubMed
-
- MacMahon S, Collins R. Reliable assessment of the effects of treatment on mortality and major morbidity, II: observational studies. Lancet. 2001;357:455–462. - PubMed
-
- Fewell Z, Davey Smith G, Sterne JAC. The impact of residual and unmeasured confounding in epidemiologic studies: a simulation study. Am J Epidemiol. 2007 Sep 15;166(6):646–655. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
